All Articles


Pharmacist’s Application to Practice: Eflornithine for High-Risk Neuroblastoma
Taylor Gullickson, PharmD, PGY1 Pharmacy Resident and Alexis Kuhn, PharmD, BCOP, Pediatric Oncology Pharmacist, from Mayo Clinic Rochester, Minnesota write about Eflornithine for High-Risk Neuroblastoma.


Late-Breaking HOPA News: COMMANDS Study for Myelodysplastic Syndrome
The COMMANDS study was a phase 3, open-label, multicenter, randomized controlled trial. Patients were eligible for enrollment if they were 18 years or older, diagnosed with very low risk, low risk or intermediate risk MDS, ESA-naïve, and requiring red blo
